C orticosteroids (CSs) have been used to treat patients with active inflammatory bowel disease (IBD) for nearly 50 years. In 1955, Truelove and Witts showed that oral cortisone beginning at a dose of 100 mg daily effectively induced remission in patients with active ulcerative colitis (UC). 1 Subsequently, in 1979, Summers et al. participating in the National Cooperative Crohn's Disease Study showed that prednisone beginning at a dose of 60 mg daily effectively induced remission in patients with active Crohn's disease (CD). 2 Because CSs are rapidly active and highly effective, they are often the intervention of choice for the initial management of moderately to severely active CD and UC. 3, 4 Response to CSs has been defined as clinical improvement after treatment with high-dose oral CS (40 -60 mg prednisone or equivalent) within 30 days or clinical improvement after treatment with high-dose intravenous CS within 7-10 days. 5, 6 Conversely, patients who fail to respond to CSs within this timeframe have been defined as CS resistant or CS refractory. Patients who initially respond to CSs but then relapse with CS tapering or shortly after CS discontinuation and require reinstitution of CS therapy at doses of 10 -30 mg/day to maintain symptom control have been defined as CS dependent. 5 The natural history of patients with CD or UC who require CS treatment is largely unknown. In 1994, Munkholm et al. described the frequency of CS resistance and dependence in a population-based cohort of Danish patients with CD. 5 We report here a population-based, 1-year natural history study of an inception cohort of patients from Olmsted County, Minnesota, after receiving their first course of CS therapy for active CD or UC.
Materials and Methods

Design of the Study
The study was a population-based inception cohort study. It has been reported previously that 173 patients were diagnosed with CD and 185 patients were diagnosed with UC in Olmsted County, Minnesota, between the years of 1970 and 1993. 7, 8 These patients had been identified using the resources of the Rochester Epidemiology Project, a linked medical diagnostic index that exploits the unique healthcare delivery system of Olmsted County and allows for true populationbased studies of disease. 9 Four patients (2 from each group) have since withdrawn research authorization, leaving 171 and 183 records, respectively, available for review. The medical records of those patients were previously abstracted through the year 1996 for patient characteristics (sex, age at diagnosis, duration of IBD, extent of IBD, and medications used for IBD before 1997). For the present study, eligible patients were residents of Olmsted County, Minnesota, diagnosed with CD or UC between 1970 and 1993 who were treated with oral or intravenous CSs before 1997. 10 The medical records for these patients were re-reviewed by a single reviewer (W.A.F.) and abstracted through the year 1997 for medication use, details of CS therapy (type of CS, initial CS dose, and duration of CS therapy including attempts to taper dose), clinical symptoms (stool frequency, rectal bleeding, fecal pus or mucus, abdominal pain, fever, weight loss, and extraintestinal symptoms), and operation for IBD. The institutional review boards of the Mayo Clinic and Olmsted Medical Center approved the study.
CS Therapy
In most patients, CS therapy was administered as oral prednisone. The initial prednisone doses ranged from 40 to 60 mg/day, and individual treating physicians attempted prednisone taper over a variable period of 3-6 months.
Outcome Measures
Immediate outcome. Thirty days after starting CS therapy, patients were classified into 1 of 3 clinical response categories as described previously. 5 1. Complete remission: defined as total regression of clinical symptoms (Յ2 bowel movements/day; no blood, pus, or mucus in feces; and no abdominal pain, fever, weight loss, or extraintestinal symptoms). 2. Partial clinical remission: regression of clinical symptoms (Յ4 stools/day; blood, pus, mucus in feces; or abdominal pain; or all 4 less than daily and no systemic symptoms, such as fever or weight loss). 3. No response: no regression of clinical symptoms.
One-year outcome. One year after starting CS therapy, patients were classified into 1 of 3 outcome categories.
1. Prolonged response: maintenance of complete or partial remission after CS therapy was completed. Patients who required subsequent courses of CSs but maintained complete or partial response and were steroid free at the end of 1 year were included in the prolonged response outcome group. 2. CS-dependent: continued CS therapy at year-end caused by relapse after CSs were discontinued or caused by relapse at dose reduction impeding discontinuation of CS therapy. Patients who required surgical resection (see below) and were also steroid dependent at 1 year were counted in the surgical resection group. 3. Surgical resection: relapse within 1 year after CS therapy was initiated, resulting in surgical resection.
Statistical Analysis
Logistic regression analysis was used to assess the 30-day response to a patient's initial course of CSs, i.e., partial or complete response vs. no response was the binary-dependent variable. Each predictor was examined in separate models, and each model included the type of IBD as a covariate. The individual potential risk factors of interest assessed included sex, age at diagnosis, concomitant medication, interval from IBD diagnosis to start of first CS course, and disease extent. An ordinal logistic regression analysis was also used to examine 30-day response coded as ordered categories: complete vs. partial vs. no response. These results were consistent with the binary logistic regression and are not reported. A multiple stepwise logistic regression analysis was not undertaken because of the limited number of patients (n ϭ 22) in the "no response" category at 30 days. The Kaplan-Meier survival method was used to estimate the cumulative probability of surgery subsequent to the initial course of CSs. One-year sustained response was assessed in the same manner as the 30-day response. Sustained response was defined as having no surgery by 1 year and not being treated with prednisone at 1 year. For the 3 patients with UC who died within the first year, 2 died being treated with prednisone and were considered failed responses and the third died while not being treated with prednisone and without having had surgery. This patient was considered to have had a sustained response. To assess for potential temporal trends that may have impacted the outcome measures over time, the data were summarized using confidence intervals according to the first 11 years (1970 -1980) and the subsequent 13 years (1981-1993). A two-sided ␣ level of 0.05 was used to indicate statistical significance. Ninety-five percent confidence intervals (CIs) were estimated using the exact binomial distribution.
Results
Patients Seventy-four of 171 patients with CD (43%; 95% CI, 36%-41%) and 63 of 183 patients with UC (34%; 95% CI, 28%-42%) received CS therapy. The demographic characteristics for these patients, including sex, age at diagnosis, disease duration at first CS therapy, site of disease, concomitant therapy, and history of intestinal resection before first CS therapy, are shown in Table 1 .
Immediate Outcome
Among the 74 patients with CD who received CS therapy, 43 (58%; 95% CI, 46%-69%) were in complete remission, 19 (26%; 95% CI, 16%-37%) were in partial remission, and 12 (16%; 95% CI, 9%-27%) had no response after 30 days (Figure 1) . Eleven of 12 patients with CD who were nonresponders underwent intestinal resection after a median of 34 days (range, 10 -251 days). Similarly, among 63 patients with UC who received CS therapy, 34 patients (54%; 95% CI, 41%-67%) were in complete remission, 19 (30%; 95% CI, 19%-43%) were in partial remission, and 10 (16%; 95% CI, 8%-27%) had no response after 30 days ( Figure  1) . Nine of 10 patients with UC who were nonresponders underwent colectomy after a median of 33 days (range, 11-252 days). Adjusting for IBD diagnosis, the logistic regression analysis indicated that only concomitant treatment with mesalamine or sulfasalazine was a statistically significant predictor of immediate outcome (P ϭ 0.04; Table 2 ). The probability of complete remission, partial remission, or no response did not change significantly between the time periods of 1970 -1980 and 1981-1993 for either CD or UC (Table 3) .
One-Year Outcome
Patient visits at a median of 1.1 years (range, 0.2-12.4 years) were used to determine 1-year outcome status. Approximately 1 year after initiation of CS therapy, 24 patients with CD (32%; 95% CI, 22%-44%) had sustained a prolonged response, 21 (28%; 95% CI, 19%-40%) were CS dependent, 28 (38%; 95% CI, 27%-50%) had undergone surgical resection, and 1 (1%) was lost to follow-up ( Figure 2 and Table 4 ). Five patients (7%) in the postsurgery group were also CS dependent. The cumulative risk of intestinal resection over 1 year after starting CS therapy for CD is shown in Figure 3A . Similarly, 1 year after initiation of CS therapy for UC, 31 patients (49%; 95% CI, 36%-62%) had noted prolonged response, 14 (22%; 95% CI, 13%-34%) were CS dependent, and 18 (29%; 95% CI, 18%-41%) had undergone colectomy. A total of 3 patients (4%) with UC had died of unrelated causes before 1 year (Figure 2 and Table 4 ). Two of these patients were being treated with prednisone at the time of death and were considered steroid dependent. The third patient was not being treated with prednisone at death and had not had surgery. This patient was considered as a prolonged response. The cumulative incidence of colectomy over 1 year after starting CS therapy for UC is shown in Figure  3B . Logistic regression for the 1-year outcome showed a borderline association with the type of IBD (proctitis ϩ proctosigmoiditis vs. CD) (P ϭ 0.05). However, no statistically significant association was detected for any of the other potential risk factors ( Table 2 ). The probability of prolonged response or CS dependent/operation did not change significantly between the time periods of 1970 -1980 and 1981-1993 for either CD or UC (Table 3) .
Discussion
Several important conclusions can be drawn from this population-based inception cohort study of the natural history of IBD after CS therapy. First, only 43% of patients with CD and 34% of patients with UC ever required CS therapy. Second, only 16% of patients with CD and 16% of patients with UC failed to respond to CS therapy. Finally, CS dependence and surgery occurred commonly in patients with either CD or UC who required CS therapy, even among those who initially responded to treatment. These findings are discussed further below.
There are few population-based natural history data on the clinical course of patients with IBD. Forty-three percent of patients with CD in our study required treatment with CSs. These results are similar to those from the only other population-based inception cohort study, which reported that 56% of patients with CD from Copenhagen County, Denmark, eventually required CS therapy. 5 Similarly, 34% of patients with UC in our study required treatment with CSs. There are no other comparable population-based data for patients with UC. These seemingly surprising results are actually consistent with previous reports on both cohorts that have indicated that the overall clinical course of CD and UC in the community is relatively mild. 10 -12 Our populationbased study avoided referral bias that exists in most other natural history studies. 13, 14 Thus, we believe these population-based studies are among the most accurate available for white populations in North America and Western Europe. Approximately 16% of our patients with IBD did not respond to CS therapy. Again, these results confirm the only other existing population-based data. Munkholm et al. reported that 20% of Danish patients with CD did not respond to CSs. 5 Similarly, Langholz et al. reported a 9% colectomy rate in the year of diagnosis in Danish patients with UC. 12 The investigators comment that patients with UC underwent colectomy after "high-dose glucocorticoid treatment"; thus, the 9% colectomy rate could be considered a surrogate for failure to respond to CSs. Although 84% of our patients with CD and UC initially responded to CSs, only 32% of patients with CD and 49% of patients with UC maintained remission without surgery or prolonged CS therapy over the ensuing year. These findings indicate that the need for CS therapy is a marker of relatively poor prognosis for both diseases.
To allow a direct comparison to the Copenhagen County study of CS dependence in patients with CD, 5 an intermediate outcome, 30 days after discontinuation of CS therapy, was also analyzed. In our study, the outcome These numbers are comparable to the 55% rate of prolonged response and 45% rate of CS dependence described by Munkholm et al. 5 Surgery within 12 months was required frequently in patients with IBD who initiated therapy with CSs. Twenty-eight patients with CD (38%) and 18 patients with UC (29%) required operation within the year. Thus, the need for treatment with CSs places a patient at high risk of requiring colectomy within the year.
The observational experience for this natural history study for the most part predates the introduction of immunosuppressive therapies such as azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, and infliximab into clinical practice in Olmsted County. Use of these therapies first began in the county in the early 1990s and has steadily expanded since. There was little change in the medical therapy of CD and UC over the period of this study, which is probably why there were no significant temporal trends towards improved outcomes for the time period of 1981-1993 compared with 1970 -1980. It is reasonable to speculate that the more frequent use of immunosuppressive agents for maintenance of steroid-induced remission and treatment of steroid dependency could reduce the rate of operation in patients with CD and UC who require treatment with CSs. [15] [16] [17] [18] [19] [20] [21] Similarly, preliminary data with infliximab and the humanized anti-tumor necrosis factor antibody CDP571 suggest that these biotechnology agents are also steroid sparing. 22, 23 Future natural history studies in this patient population should test the hypothesis that immunosuppressive or biotechnology therapy is "surgery-sparing" in patients who require treatment with CSs.
In conclusion, Ͻ50% of patients with IBD ever require treatment with CSs. Of those who do require CS therapy, 84% are initially responsive and 16% are resistant. Among those who are initially CS responsive, CS dependence and operation occur frequently, indicating that the need for treatment with CSs is a marker of poor prognosis. Studies that evaluate the efficacy of early immunosuppressive or biotechnology therapy in patients with IBD who require treatment with CSs for avoidance of CS dependency and operation are needed. 
